Condensation Methods for the Determination of Darunavir in Pure and Pharmaceutical Formulations

M.L.N. Acharyulu\textsuperscript{1}, P.V.S.R. Mohana Rao\textsuperscript{2}, I. Siva Ramakoti\textsuperscript{3}

\textsuperscript{1}Associate Professor, Centurion University of Technology and Management, Andhra Pradesh-530017, India
\textsuperscript{2}Research Scholar, Department of Engineering Chemistry, A.U. College of Engineering (A), Visakhapatnam-530003, A.P.; India
\textsuperscript{3}Assistant Professor, Department of Chemistry, Centurion University Of Technology and Management, Odisha-761211, India

Abstract: Two visible spectrophotometric methods were developed A and B for the determination of Darunavir in pure and pharmaceutical formulations. The methods are based on condensation reaction with PDAB (Method-A) and ONB (Method-B) in presence of acidic medium with the primaryamine group in DNV. The coloured products exhibit absorption $\lambda_{max}$ at 639 nm and 452 nm for methods A and B respectively. Regression analysis of Beer-Lambert plots showed good correlation in the concentration ranges 10-60 μg/ml, 50-300 μg/ml, correlation co-efficients are 0.9983, 0.9989; Sandell's sensitivities are 9.9833 x 10^{-3}, 3.0456 x 10^{-2} (1 mole cm$^{-1}$); and molar absorptivity values are 5.4857 x 10^{4}, 1.7981 x 10^{4} (μg cm$^{-2}$) for methods A and B respectively. The proposed methods are applied to commercial available formulations and the results are statistically compared with those obtained by the UV reference method and validated by recovery studies. The results are found satisfactory and reproducible. These methods are applied successfully for the estimation of the DNV in the presence of other ingredients that are usually present in formulations. These methods offer the advantages of rapidity, simplicity and sensitivity and low cost without the need for expensive instrumentation and reagents.

Key words: Condensation, PDAB, ONB, Regression Analysis.
Introduction and Experimental

![Structure of Darunavir](image)

**Fig.1 Structure of Darunavir**

Darunavir (DNV) is an oral anti-retroviral agent (Fig.1) which selectively inhibits the cleavage of Human immunodeficiency virus (HIV-1) encoded Gas-polyproteins in infected cell, thereby preventing the formation of mature virus. Darunavirethanolate is chemically \([(1S,2R)-3-[(4-amino phenol) sulfonyl](2-methyl propyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester monoethanolate\(^1\). Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from the treatment-experienced patients with multiple resistance mutations to Protease inhibitors\(^2\). It blocks HIV protease, an enzyme which is needed for HIV to multiply. According to in vitro experiments, DNV was active against HIV-1 with PI-resistance mutations and against PI-resistance clinical isolates\(^3,4\). This drug is effective in patients experienced in anti-retroviral treatment, such as those carrying HIV-1 strains which are resistance to more than one PI\(^5\). The use of advanced instrumentation techniques for the analysis of drugs has been discussed elsewhere\(^6\). Literature survey revealed that different analytical methods have been reported for the determination of DNV in plasma using liquid chromatography coupled with tandem mass spectroscopy\(^7\) simultaneous determination of DNV with other anti-retroviral agents in plasma\(^8,9\). Few HPTLC methods for determination of DNV in rat plasma and in tablet dosage form its application to pharmacokinetics studies\(^10\). Infrared Spectroscopy method for determination of Darunavir in tablets\(^11\). Few methods had been developed for determination of DNV by HPLC\(^12-17\) and electrophoretic method\(^18\) for the separation of DNV. The analytical useful functional groups in DNV have not been fully exploited for designing suitable visible spectrophotometric methods and so still offer a scope to develop more visible spectrophotometric methods with better sensitivity, precision and accuracy. The author has made some attempts in this direction and succeeded in developing six methods in part-A. All these methods have extended pharmaceutical formulations as well. Literature survey reveals that reported HPLC methods require more time for sample analysis resulting in lesser throughput. Therefore the author has made attempt to develop rapid RP-HPLC method in part-B for determination and estimation DNV in bulk and tablet dosage form. Validation as per ICH and USFDA guidelines\(^19,20\) is done along with stress degradation study. The aim of the present study is to develop a simple, precise and accurate reversed-phase HPLC method for the development and validation of DNV in bulk drug samples and in pharmaceutical dosage form.

**Instrument Used**

A Schimadzu UV-Visible spectrophotometer 1801 with 1 cm matched quartz cells was used for all spectral and absorbance measurements. A Systronics digital pH meter 361 was used for pH measurements.

**Preparation of standard Drug solution**

The stock solution (1 mg/ml) of Darunavir (DNV) was prepared by dissolving 100 mg of it in 100 ml of millipore-distilled water. A portion of this stock solution was diluted stepwise with the distilled water to obtain the working standard DNV solution of concentrations 4-600 µg/ml.
Procedure of Assay of DNV in formulations

An accurately weighed amount of formulation (tablet) equivalent to 100 mg of drug was dissolved in 20 ml of distilled water, shaken well and filtered. The filtrate was further diluted to 100 ml with distilled water to get 1 mg/ml solution of drug in formulations.

One ml of this solution was furthered diluted to 25 ml to get 40 µg/ml solution. The absorbance of the solution was determined $\lambda_{\text{max}}$ 223 nm (Fig.5.01). The quantity of the drug was computed from the Beer’s law plot (Fig. 5.02) of the standard drug in distilled water.

---

**Fig.2** Absorption spectra of DNV in methanol (UV reference method)

**Fig.3** Beer’s law Plot of DNV in methanol (UV reference method)

**Recommended Procedures:**

After systematic and detailed study of the various parameters involved, as described under results and discussion in this chapter, the following procedures were recommended for the determination of DNV in bulk samples.
Method-A

To each of 10 ml calibrated tubes, aliquots (0.1 – 0.6 ml, 60 µg/ml) of standard DNV solution, 2.0 ml of PDAB and 3.0 ml of conc. sulphuric acid were added successively and the total volume in each flask was brought to 9 ml by the addition of methanol and placed in a heating water bath for 15 minutes. Then the flasks were cooled and made up to the mark with methanol and absorbance was measured after 5 min. at $\lambda_{\text{max}}$650 nm (Fig.4) against a reagent blank prepared in a similar way. The amount of DNV in sample solution was obtained from the Beers-Lambert’s plot (Fig 5).

Method-B

Into a series of 10 ml calibrated tubes, aliquots of standard DNV solution (0.1-0.6ml, 60 µg/ml) 1ml of ortho nitro benzaldehyde, 2 ml of sulphuric acid and 2 ml of methanol was added successively and solution allowed to stand for 5 minutes. The solution made up to the volume by adding distilled water. The absorbance of each solution was measured at $\lambda_{\text{max}}$451 nm (Fig.6) against reagent blank prepared in similar manner. The amount of DNV in the sample was computed from Beer’s-Lamberts Law (Fig.7).

![Fig 4 Absorption spectra of DNV:PDAB/H$_2$SO$_4$](image)

![Fig 5 Absorption spectra of DNV: ONB/H$_2$SO$_4$](image)
Fig. 6 Beer’s plot of DNV: PDAB/H$_2$SO$_4$

Fig. 7 Beer’s plot of DNV: ONB/H$_2$SO$_4$

Table 1. Optical and Regression characteristics, precision and accuracy of the proposed methods for DNV

| Sl.No | Parameter                                      | Method-A         | Method-B         |
|-------|-----------------------------------------------|------------------|------------------|
| 1     | Wave length $\lambda_{max}$ (nm)              | 639              | 452              |
| 2     | Beer’s law limits ($\mu$g ml$^{-1}$)          | 10-60            | 50-300           |
| 3     | Detection limits ($\mu$g ml$^{-1}$)           | 2.4290           | 10.7554          |
| 4     | Molar absorptivity (1 mole cm$^{-1}$)         | $5.4857 \times 10^4$ | $1.7981 \times 10^5$ |
| 5     | Sandell’s sensitivity ($\mu$g cm$^{-2}$/0.001 absorbance unit) | $9.9833 \times 10^{-3}$ | $3.0456 \times 10^{-2}$ |
| 6     | Regression equation ($Y = a + bC$) Slope (b)  | 0.0103           | 0.0033           |
| 7     | Standard deviation of slope ($S_b$)           | $2.1414 \times 10^{-4}$ | $6.0757 \times 10^{-3}$ |
| 8     | Intercept (a)                                 | -0.0049          | 0.0029           |
| 9     | Standard deviation of intercept ($S_a$)       | $8.3396 \times 10^{-3}$ | $1.1831 \times 10^{-2}$ |
### Table 2: Assay and recovery of DNV in Pharmaceutical Formulations

| Sample  | Amount taken (mg) | Amount found by proposed methods | Reference Methods | Percentage recovery by proposed methods |
|---------|-------------------|----------------------------------|-------------------|----------------------------------------|
|         |                   | Method-A | Method-B             | Method-A | Method-B             | Method-A | Method-B             |
| Tablet I| 300               | 299.12 ±0.175 | 299.25 ±0.225 | 299.3 ±0.186 | 99.802 ±0.054 | 99.767 ±0.079 |
|         |                   | F=1.27 t=0.42 | F=1.466 t=1.05 |                         |                         |                     |
| Tablet II| 300              | 299.15 ±0.378 | 299.20 ±0.408 | 299.25 ±0.401 | 99.270 ±0.084 | 99.573 ±0.103 |
|         |                   | F=1.12 t=1.84 | F=1.034 t=0.96 |                         |                         |                     |

### Chemistry of coloured species in the present investigation

DNV possesses different functional moieties such as primary amine, tertiary amine and sulphonyl groups of varied reactivity. The methods are proposed here based on condensation reaction with PDAB (Method-A) and ONB (Method-B) in presence of acidic medium. In the present investigation, it is observed that under acidic conditions the primary group in DNV forms coloured condensation product with aromatic aldehyde PDAB (Method-A), ONB (Method-B) in the presence of H₂SO₄ in non-aqueous medium. The nature of coloured species obtained with PDAB and ONB are represented in the schemes 1,2 respectively.

**Scheme 1**

\[
R' \quad R'' \quad CHO + RNH₂ \xrightarrow{H₂SO₄} \quad R' \quad R'' \quad CH = NR
\]

\[ Vn: \quad R': OH; R'": OM \]

\[ PDAB: R': N(Me)₂; R'": F \]

**Scheme 2**

\[
CHO + RNH₂ \xrightarrow{H₂SO₄} \quad CH = NR
\]

\[ NO₂ \]

\[ NO₂ \]
For above all

Results and Discussion

Optimum operating conditions used in the procedure were established adopting variation of one variable at a time (OVAT) method. The effect of various parameters such as were studied. Volume of PDAB, volume of conc. H$_2$SO$_4$ on colour development, effect of order of addition of reagents on colour development, effect of temperature ($^\circ$C) shaking time (min), solvent for final dilution, stability period after final dilution were studied for method-A, and effect of volume of ONB required for condensation, volume of H$_2$SO$_4$, effect of CH$_3$OH, reaction time and stability period after final dilution were studied for method-B.

The optical characteristics such as Beer’s law limit, Sandell’s sensitivity, molar absorptivity, percent relative standard deviation, (calculated from the six measurements, Regression characteristics like standard deviation of slope (S$_b$), standard deviation of intercept (S$_a$), standard error of estimation (S$_e$), and % range of error (0.05 and 0.01 confidence limits) were calculated and the results are summarized in Table-1. Commercial formulations containing DNB were successfully analyzed by the proposed methods. The values obtained by the proposed and reference methods for formulations were compared statistically by the t-test and F-test and found not to differ significantly. As an additional demonstration of accuracy, recovery experiments were performed by adding a fixed amount of the drug to the pure analyzed formulations at three different concentration levels. These results are summarized in Table-2.

Conclusion

The proposed methods for DNV determination have many advantages over other analytical methods due to its rapidity, lower cost and environmental safety. Unlike HPLC, LC procedures, the instrument is simple and is not costly. Economically, all the analytical reagents are in expensive and available in any analytical laboratory. The proposed methods report new ways for the determination of DNV in pharmaceuticals.

References

1. Ghosh AK, Dawson ZL, Mitsuya H. Bio.Org. Med. Chem; 2007, 15(24), 7576–80.
2. S. Meyer, H. Azojin, D. Surleraux, TMC 114, Antimicrob Agents Chemother. 2005, 49, 2314-2321.
3. N. King, M. Jeyabaran, E. Naliyaika, P. Wifgerinck, M. Bethune, C. Schiffer. J.Virol, (2004), 78, 12012-12021.
4. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, A. Lazzarin, A. Wohtmann, C. Katlama, T. Wilkin. Lancet, 2007, 369, 1169-1178.
5. "Instrumental Methods of Analysis" by Galen W. Ewing, McGraw Hill International Edition, p.48, 378.
6. AmitPatel, and Ashlesha Makwana. An ESI-LC-MS/MS method for simultaneous Estimation of Darunavir and Ritonavir in human plasma, International Journal of Research in Pharmaceutical and Biomedical science. 2013, 4(4), 1138-47.
7. Nageshwar Rao, Ram chandra, Santoshkumar. RP-HPLC separation and Characterisation of unknown impurities of a novel HIV-1protease inhibitor Darunavir by ESI-MS and 2D NMR Spectroscopy, J Pharm Biomed Anal. 2013, 75, 186-191.
8. Avolio, M. Siccardi, M. Sciandra, L. Baietto. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients, J Chromatogr B. 2007, 859, 234-240.
9. Hari Babu, Sisla Ramakrishna, Kirankumar, Ramesh, Sita Devi. HPLC method for the Determination of Darunavir in Plasma and its application in Pharmako Kinetic Studies, J. liq. Chromatography Releated Technol. 2013, 36, 169-179.
10. Ana Carolina Kongana, Herida Regina, Ana Carolina Kongana, Herida Regina. Development and validation of Infra Red Spectroscopy for Determination of Darunavir in Tablets, Chem. Phy. Chem. 2013, 3, 1-6, Phy. Chem, Phy. Chem. 2013, 3, 1-6.
11. G. Raveendra Babu, A. Lakshmana Rao and J. Venkateshwara Rao. Development and Validation of Novel HPLC Method for Estimation of Darunavir in Pharmaceutical Formulations, International Journal of Research in Pharmacy and chemistry. 2013, 3, 438-443.
12. Bhavani, B. Patel, B. N. Suhagia. Simultaneous Determination and validation of Darunavir Ethanolate and Ritonavir in binary mixture by Liquid chromatography, International Journal of Pharm Tech Research. 2012, 4(4), 1450-56.
13. Raveendra B. Ganduri, Ramprasad A. Lanka, Srinivasu Pamidi, Jayachandra R. Poddaredigari, JVLNS Rao. NEW RP-HPLC METHOD FOR THE DETERMINATION OF DARUNAVIR IN TABLET DOSAGE FORM., Asian J. Pharm. Res. 2011, 1(1), 10-14.
14. L. Satyanarayana, S. V. Naidu, M. Narasimha Rao, Alokkumar and K. Suresh. The Estimation of Darunavir in Tablet dosage form by RP-HPLC., Asian J. Res. Pharm. Sci. 2011, 1(3), 74-76.
15. Manisha B. Mane, Pranali J. Gaikawad, Anuja V. Patil, Aashish S. Mogale. RP-HPLC Method for Determination of Darunavir in Bulk and Pharmaceutical Preparations. Int. J. Pharm. Sci. 2013, 21(2), 20-23.
16. Gholve, Sachin B., Asware Baburao S., Kadam Shrihari C., Bhusure Omprakash G. and Thonte Sanjay S. Development and Validation of a simple UV Spectrophotometric method for the determination of Darunavir Ethanolate both in bulk and Marketed Dosage Formulations, World Journal of pharmaceutical research. 2015, 4(3), 1276-1283.
17. B. V. Rami Reddy, G. Jyothi, B. S. Reddy, N. V. V. S. S. Raman, K. Subhash Chander Reddy, C. Rambabu, Stability-Indicating HPLC Method for the Determination of Darunavir Ethanolate, journal of Chromatographic Science, 2013, 51(5), 471-476.
18. S. Leonard, A. Schepdael, T. Lvanyi, I. Lazar, J. Rosier, M. separation of diastereoisomers of a new human immunodeficiency virus protease inhibitor, Vanstockem. Development of a capillary electrophoretic method for the, Electrophoresis. 2005, 26, 627.
19. International Conference on Harmonization (ICH), Q2(R1), November 2005.
20. Authority of the United States Pharmacopeial Convention. The United States Pharmacopeia (USP34), National Formulary (NF 29). Maryland, 2011.

*****